

**Date:** April 21, 2026

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
**Scrip Code: 544292**

**National Stock Exchange of India Limited**

Exchange Plaza, C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Symbol: ONESOURCE**

Dear Madam/ Sir,

**Sub: Press Release:**

Please find enclosed herewith Press Release issued by the Company titled:

**Orbicular's Partner secures tentative U.S. ANDA approval for a generic version of Ozempic®  
(Semaglutide Injection), supported by OneSource as CDMO partner**

You are requested to kindly take the same on record.

For and on behalf of  
**OneSource Specialty Pharma Limited**

**Trisha A**  
Company Secretary and Compliance Officer  
Membership Number: A47635

*Encl. as below*

## **Orbicular’s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic® (Semaglutide Injection), supported by OneSource as CDMO partner**

**Bangalore, India, April 21, 2026** – OneSource Speciality Pharma Limited (BSE: 544292, NSE: ONESOURCE) today announced that its partner Orbicular Pharmaceutical Technologies (“Orbicular”), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval for an Abbreviated New Drug Application (ANDA) for a generic version of Ozempic® (Semaglutide Injection). OneSource is the contract development and manufacturing organization (CDMO) partner for this product.

This milestone highlights a closely integrated development-to-submission model: Orbicular led the product development and technical program for this complex peptide, while OneSource supported the program as the CDMO partner, providing end-to-end manufacturing capabilities for the U.S. market filing. The collaboration is designed to ensure reliable commercial supply from OneSource’s US-FDA approved flagship site in Bangalore.

**Mr. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said:** *“We are pleased to announce that our partner Orbicular, along with its front-end partner (the ANDA holder), has received tentative approval for a generic version of Ozempic® (Semaglutide Injection). This milestone reflects Orbicular’s scientific expertise and OneSource’s CDMO capabilities, supported by our US-FDA approved manufacturing site.”*

OneSource continues to strengthen its position as a global CDMO partner for drug-device combinations, complex injectables and specialty pharmaceutical products through strategic collaborations such as the one with Orbicular, where OneSource serves as the CDMO partner supporting manufacturing and commercial supply readiness.

### **About OneSource Specialty Pharma Limited**

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit [www.onesourcecdmo.com](http://www.onesourcecdmo.com).

### **About Orbicular**

Orbicular is a partnership driven, B2B specialty pharmaceutical company focused on designing, developing, and delivering complex generics and specialty pharmaceutical products. With integrated capabilities spanning development, advanced analytical characterization, regulatory strategy, and technology transfer, Orbicular enables partners to bring high-value, technically complex products to global markets.

For further information, please contact:

<p><b><u>Institutional Investors</u></b> <b>Anurag Bhagania</b> CFO</p> <p><b>Tejaswani Fotedar:</b> +91 9004331391 Email: <a href="mailto:investor-relations@onesourcecdmo.com">investor-relations@onesourcecdmo.com</a></p>	<p><b><u>Corporate Communication</u></b> <b>Pallavi Panchmatia:</b> +91 8951939181 Email: <a href="mailto:pallavi.panchmatia@onesourcecdmo.com">pallavi.panchmatia@onesourcecdmo.com</a> <b>Abhilash Mukherjee:</b> +91 89044 28907 Email: <a href="mailto:abhilash.mukherjee@onesourcecdmo.com">abhilash.mukherjee@onesourcecdmo.com</a> <b>Harsh Sheth:</b> +91 9870631557 Email: <a href="mailto:harsh.sheth@msslgroup.com">harsh.sheth@msslgroup.com</a></p>
---	--